SQZ Biotechnologies, a clinical-stage biotechnology company located in Massachusetts, is focused on developing innovative cell therapies to combat cancer, autoimmune disorders, infectious diseases, and other serious medical conditions. The company's flagship product candidate, SQZ-PBMC-HPV, is currently undergoing a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents to treat patients with HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. SQZ Biotechnologies is also working on the development of SQZ-AAC-HPV, which is currently in Phase I clinical trials for HPV16+ advanced or metastatic solid tumors, as a monotherapy and in combination with immune-oncology agents. Additionally, the company is exploring two other platforms, SQZ Activating Antigen Carriers, and SQZ Tolerizing Antigen Carriers, to develop future products and further advance its pipeline. Headquartered in Watertown, Massachusetts, SQZ Biotechnologies was founded in 2013 and has quickly established itself as a formidable player in the highly competitive biotechnology industry. With its cutting-edge technology and promising product pipeline, the company is poised to make a significant impact in the field of cell therapy in the years to come.
Serica Energy PLC's ticker is SQZ
The company's shares trade on the LSE stock exchange
They are based in London, England
There are 51-200 employees working at Serica Energy PLC
It is http://www.serica-energy.com/
Serica Energy PLC is in the Basic Materials sector
Serica Energy PLC is in the Independent Oil & Gas industry
The following five companies are Serica Energy PLC's industry peers: